Trials / Completed
CompletedNCT01872065
Safety and Tolerability Study of ARC-520 in Healthy Volunteers
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 in Normal Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Arrowhead Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of ARC-520 in normal, adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARC-520 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2014-09-01
- Completion
- 2014-11-01
- First posted
- 2013-06-07
- Last updated
- 2025-12-26
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT01872065. Inclusion in this directory is not an endorsement.